|
SG10202108118RA
(en)
|
2001-11-13 |
2021-08-30 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3567106A1
(en)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
KR20140041505A
(ko)
|
2011-04-29 |
2014-04-04 |
셀렉타 바이오사이언시즈, 인크. |
조절 b 세포 유도를 위한 관용원성 합성 나노운반체
|
|
CA2856137A1
(en)
|
2011-11-22 |
2013-05-30 |
The Children's Hospital Of Philadelphia |
Virus vectors for highly efficient transgene delivery
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
US9539307B2
(en)
|
2012-09-17 |
2017-01-10 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
AU2014229051B2
(en)
|
2013-03-15 |
2020-07-16 |
The Children's Hospital Of Philadelphia |
Vectors comprising stuffer/filler polynucleotide sequences and methods of use
|
|
BR112015027291A8
(pt)
|
2013-05-03 |
2019-12-24 |
Selecta Biosciences Inc |
uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
|
|
PT3024498T
(pt)
*
|
2013-07-22 |
2020-03-06 |
Childrens Hospital Philadelphia |
Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
AU2014346987A1
(en)
*
|
2013-11-05 |
2016-06-23 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
CA3276269A1
(en)
|
2014-03-18 |
2026-03-02 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
DK3628334T5
(da)
|
2014-03-21 |
2024-09-02 |
Genzyme Corp |
Genterapi til behandling af retinitis pigmentosa
|
|
CA2946392A1
(en)
|
2014-04-25 |
2015-10-29 |
James M. Wilson |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
CN105396143B
(zh)
*
|
2014-09-01 |
2020-06-26 |
江苏命码生物科技有限公司 |
埃博拉病毒特异性的miRNA以及通过miRNA抑制埃博拉病毒的方法
|
|
WO2016037164A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
CN107106689A
(zh)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
IL292999A
(en)
|
2014-11-14 |
2022-07-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CN112410338A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
RU2726131C2
(ru)
|
2015-05-22 |
2020-07-09 |
Дмитрий Дмитриевич Генкин |
Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
|
|
PT3313991T
(pt)
|
2015-06-23 |
2024-09-27 |
Childrens Hospital Philadelphia |
Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos
|
|
US11389483B2
(en)
*
|
2015-07-10 |
2022-07-19 |
Duke University |
Methods for treating pain
|
|
AU2016323575B2
(en)
|
2015-09-17 |
2022-10-27 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for GALGT2 gene therapy
|
|
PE20181338A1
(es)
|
2015-09-24 |
2018-08-21 |
Biomarin Pharm Inc |
Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
|
|
DK3365438T3
(da)
*
|
2015-10-21 |
2021-07-12 |
Us Health |
Codon-optimeret reduceret-størrelse atp7a cdna og anvendelser ved behandling af kobbertransportlidelser
|
|
EP3364996B1
(en)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
TWI823830B
(zh)
|
2015-11-13 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
|
|
CN116479001A
(zh)
|
2015-11-13 |
2023-07-25 |
武田药品工业株式会社 |
用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
|
|
EP3377042A4
(en)
|
2015-11-16 |
2019-05-29 |
The Research Institute at Nationwide Children's Hospital |
MATERIALS AND METHOD FOR THE TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINOPATHIES
|
|
MX2018006682A
(es)
*
|
2015-12-01 |
2018-09-26 |
Spark Therapeutics Inc |
Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico.
|
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
|
CA3008142A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
CA3019126A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Spark Therapeutics, Inc. |
Cell line for recombinant protein and/or viral vector production
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
EP4407035A3
(en)
*
|
2016-04-15 |
2024-10-30 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017197355A2
(en)
|
2016-05-13 |
2017-11-16 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
SG11201809699XA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
|
KR20220108216A
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
AU2017301600B2
(en)
|
2016-07-26 |
2022-08-04 |
Biomarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
|
|
CN106344932B
(zh)
*
|
2016-08-26 |
2019-12-27 |
首都医科大学附属北京同仁医院 |
一种用于提高视网膜退行性疾病基因治疗效果的组合物及其应用
|
|
CN110650673B
(zh)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
CA3040483A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
|
WO2018082093A1
(en)
*
|
2016-11-07 |
2018-05-11 |
Wuhan Institute Of Virology, Chinese Academy Of Sciences |
Anterograde monosynaptic transneuronal tracer system
|
|
EP3562514B1
(en)
|
2016-12-30 |
2026-04-29 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating wilson's disease
|
|
US20230190958A1
(en)
|
2017-01-13 |
2023-06-22 |
Jichi Medical University |
AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
|
|
KR20190118163A
(ko)
|
2017-02-20 |
2019-10-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
가족성 고콜레스테롤혈증을 치료하기 위한 유전자 요법
|
|
US20200054711A1
(en)
*
|
2017-02-28 |
2020-02-20 |
The Penn State Research Foundation |
Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow
|
|
JOP20190200A1
(ar)
*
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
KR20230093072A
(ko)
*
|
2017-03-01 |
2023-06-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
안구 장애에 대한 유전자 치료
|
|
KR102753928B1
(ko)
|
2017-03-11 |
2025-01-14 |
셀렉타 바이오사이언시즈, 인크. |
항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
|
|
MA47800A
(fr)
|
2017-03-17 |
2020-01-22 |
Univ Newcastle |
Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
|
|
DK3596222T5
(da)
*
|
2017-03-17 |
2024-09-02 |
Res Inst Nationwide Childrens Hospital |
Adenoassocieret virusvektorfremføring af muskelspecifik mikro-dystrophin til behandling af muskeldystrofi
|
|
EA201992358A1
(ru)
|
2017-04-03 |
2020-03-24 |
Инкоудид Терапьютикс, Инк. |
Тканеселективная экспрессия трансгена
|
|
SG11201909870SA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
CN118956965A
(zh)
|
2017-05-19 |
2024-11-15 |
编码治疗公司 |
高活性调控元件
|
|
KR102386890B1
(ko)
|
2017-05-22 |
2022-04-15 |
다케다 야쿠힌 고교 가부시키가이샤 |
B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
CA3069880A1
(en)
*
|
2017-07-17 |
2019-01-24 |
Spark Therapeutics, Inc. |
Apheresis methods and uses
|
|
TWI832036B
(zh)
|
2017-08-03 |
2024-02-11 |
美商航海家醫療公司 |
用於aav之遞送之組合物及方法
|
|
BR112020002394A2
(pt)
|
2017-08-09 |
2020-07-28 |
Bioverativ Therapeutics Inc. |
moléculas de ácidos nucleicos e usos das mesmas
|
|
US12385061B2
(en)
|
2017-09-08 |
2025-08-12 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
|
|
PE20201264A1
(es)
|
2017-09-20 |
2020-11-19 |
4D Molecular Therapeutics Inc |
Variantes de capsides de virus adenoasociados y metodos de uso de estas
|
|
US11739330B2
(en)
|
2017-09-22 |
2023-08-29 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN107760719B
(zh)
*
|
2017-10-24 |
2020-09-22 |
北京领柯生物科技有限公司 |
柯萨奇病毒在过继免疫基因递送系统中的应用
|
|
ES2946747T3
(es)
|
2017-11-27 |
2023-07-25 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociado y su utilización para inhibir la angiogénesis
|
|
JP7401432B2
(ja)
|
2017-12-01 |
2023-12-19 |
エンコーデッド セラピューティクス， インコーポレイテッド |
操作されたｄｎａ結合タンパク質
|
|
CN111727243A
(zh)
*
|
2017-12-19 |
2020-09-29 |
北卡罗来纳-查佩尔山大学 |
用于跨越血-脑屏障递送病毒载体的方法和组合物
|
|
SG11202006169PA
(en)
|
2017-12-29 |
2020-07-29 |
Helixmith Co Ltd |
Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
|
|
US11905522B2
(en)
|
2018-01-16 |
2024-02-20 |
Cls Therapeutics Limited |
Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
|
|
AR114350A1
(es)
|
2018-01-31 |
2020-08-26 |
Res Institute At Nationwide ChildrenS Hospital |
Terapia genética para la distrofia muscular de cinturas del tipo 2c
|
|
AU2019215152A1
(en)
|
2018-02-01 |
2020-08-20 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
CN112004925B
(zh)
|
2018-04-05 |
2024-09-27 |
吉尼松公司 |
具有降低的肝向性的AAV9和AAVrh74的杂合重组腺相关病毒血清型
|
|
AU2019261646A1
(en)
|
2018-04-27 |
2020-11-12 |
Spacecraft Seven, Llc |
Gene therapy for CNS degeneration
|
|
CA3099704A1
(en)
|
2018-05-09 |
2019-11-14 |
Biomarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
EP3794126A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
BR112020025995A2
(pt)
|
2018-06-18 |
2021-03-23 |
Research Institute At Nationwide Children's Hospital |
administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular
|
|
WO2020006458A1
(en)
|
2018-06-29 |
2020-01-02 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
|
KR20210034013A
(ko)
|
2018-07-16 |
2021-03-29 |
박스알타 인코퍼레이티드 |
발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
|
|
KR102925832B1
(ko)
|
2018-08-09 |
2026-02-11 |
바이오버라티브 테라퓨틱스 인크. |
핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
|
|
US20220010333A1
(en)
*
|
2018-09-06 |
2022-01-13 |
The Regents Of The University Of California |
Rna and dna base editing via engineered adar recruitment
|
|
CN113383010B
(zh)
|
2018-09-28 |
2025-09-09 |
沃雅戈治疗公司 |
具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
SG11202106855YA
(en)
*
|
2019-01-04 |
2021-07-29 |
Ultragenyx Pharmaceutical Inc |
Gene therapy constructs for treating wilson disease
|
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
|
CN120324641A
(zh)
*
|
2019-02-12 |
2025-07-18 |
太空飞船七有限责任公司 |
用于治疗达农病的基因治疗载体
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
CA3131390A1
(en)
|
2019-02-26 |
2020-09-03 |
Research Institute Of Nationwide Children's Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
|
MA55087A
(fr)
|
2019-02-28 |
2022-01-05 |
Encoded Therapeutics Inc |
Compositions et procédés de traitement de laminopathies
|
|
CN109999182B
(zh)
*
|
2019-03-29 |
2023-03-07 |
四川大学华西医院 |
凝血因子在制备抗肿瘤药物中的应用
|
|
WO2020234410A1
(en)
*
|
2019-05-20 |
2020-11-26 |
Biontech Rna Pharmaceuticals Gmbh |
Therapeutic rna for ovarian cancer
|
|
WO2020243651A1
(en)
|
2019-05-29 |
2020-12-03 |
Encoded Therapeutics, Inc. |
Compositions and methods for selective gene regulation
|
|
EP3980784A1
(en)
|
2019-06-04 |
2022-04-13 |
Selecta Biosciences, Inc. |
Formulations and doses of pegylated uricase
|
|
WO2020251887A1
(en)
*
|
2019-06-10 |
2020-12-17 |
The Children's Medical Center Corporation |
Compositions and methods for the treatment of dba using gata1 gene therapy
|
|
EP4488287A3
(en)
|
2019-08-21 |
2025-03-05 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
|
|
KR20220070443A
(ko)
|
2019-08-27 |
2022-05-31 |
버텍스 파마슈티칼스 인코포레이티드 |
반복성 dna와 연관된 장애의 치료용 조성물 및 방법
|
|
EP4041315A4
(en)
*
|
2019-09-25 |
2023-11-01 |
University Of Utah Research Foundation |
Methods and compositions for the expression of constitutively active rap1a from a vmd2 promoter
|
|
US20220324928A1
(en)
*
|
2019-10-02 |
2022-10-13 |
Sangamo Therapeutics, Inc. |
Zinc Finger Protein Transcription Factors for Repressing Alpha-Synuclein Expression
|
|
JP7665609B2
(ja)
*
|
2019-10-30 |
2025-04-21 |
デシベル セラピューティクス インコーポレイテッド |
オトフェリン二重ベクター系及びそれを含む感音難聴を治療するための組成物
|
|
EP4076467A4
(en)
*
|
2019-11-04 |
2023-12-27 |
Decibel Therapeutics, Inc. |
VESTIBULAR BEARING CELL PROMOTORS AND USES THEREOF
|
|
WO2021096927A1
(en)
*
|
2019-11-13 |
2021-05-20 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Compositions and uses thereof for treating, prognosing and diagnosing pulmonary hypertension
|
|
AU2020384294A1
(en)
|
2019-11-14 |
2022-06-02 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with liver-specific gene therapy vectors
|
|
WO2021101980A1
(en)
*
|
2019-11-19 |
2021-05-27 |
The Regents Of The University Of California |
Compositions and methods of using engineered fusion proteins that bind g4c2 human repeats
|
|
US20230059344A1
(en)
*
|
2019-11-20 |
2023-02-23 |
Bavarian Nordic A/S |
Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)
|
|
IL293141A
(en)
*
|
2019-11-21 |
2022-07-01 |
Remedium Bio Inc |
Growth factor restoration
|
|
US20230021959A1
(en)
*
|
2019-12-05 |
2023-01-26 |
The Trustees Of Columbia University In The City Of New York |
Stabilization of Retromer for the Treatment of Alzheimer's Disease and Other Neurodegenerative Disorders
|
|
AU2020403155A1
(en)
*
|
2019-12-11 |
2022-06-30 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods for manufacture and uses thereof
|
|
WO2021123920A1
(en)
*
|
2019-12-18 |
2021-06-24 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
GB201918879D0
(en)
*
|
2019-12-19 |
2020-02-05 |
Ucl Business Ltd |
Treatment of chronic pain
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
EP4090381A1
(en)
*
|
2020-01-17 |
2022-11-23 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
<smallcaps/>? ? ?crx-? ? ? ? ?gene therapy for treatment ofautosomal dominant retinopathies
|
|
CN116096905A
(zh)
|
2020-02-21 |
2023-05-09 |
阿库斯股份有限公司 |
用于治疗人受试者的非年龄相关性听力损伤的组合物和方法
|
|
EP4114952A4
(en)
*
|
2020-03-05 |
2024-05-08 |
Board of Regents of the University of Nebraska |
Crispr/cas9 system for multistrain hiv-1 treatment
|
|
WO2021183755A1
(en)
*
|
2020-03-11 |
2021-09-16 |
City Of Hope |
Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
|
|
AR122409A1
(es)
|
2020-04-03 |
2022-09-07 |
Biomarin Pharm Inc |
Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021257497A1
(en)
*
|
2020-06-15 |
2021-12-23 |
Sarepta Therapeutis, Inc. |
Adeno-associated virus antibodies and fragments thereof
|
|
CN115996758A
(zh)
*
|
2020-06-19 |
2023-04-21 |
吉尼松公司 |
使sgcg在肌肉和心脏中充分表达的基因治疗表达系统
|
|
KR20230031329A
(ko)
*
|
2020-06-30 |
2023-03-07 |
칠드런스 내셔널 메디컬 센터 |
골격 근섬유 복구를 개선하기 위한 재조합 인간 산성 스핑고미엘리나제의 용도
|
|
CN111500635B
(zh)
*
|
2020-07-02 |
2020-10-09 |
北京大学第三医院（北京大学第三临床医学院） |
一种包含携带核酸分子的载体的试剂盒
|
|
CN116333984A
(zh)
*
|
2020-07-14 |
2023-06-27 |
广州泛恩生物科技有限公司 |
基于galnt2阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
|
|
CN116121275B
(zh)
*
|
2020-07-29 |
2024-11-29 |
北京三诺佳邑生物技术有限责任公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
IL300263A
(en)
|
2020-08-07 |
2023-03-01 |
Spacecraft Seven Llc |
Plakophilin-2 (PKP2) gene therapy using an AAV vector
|
|
TW202218686A
(zh)
|
2020-09-09 |
2022-05-16 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之組合物及方法
|
|
EP4228610A1
(en)
|
2020-10-13 |
2023-08-23 |
Kriya Therapeutics, Inc. |
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
|
|
US20220110970A1
(en)
*
|
2020-10-14 |
2022-04-14 |
The Texas A&M University System |
Engineered Extracellular Vesicle Delivery Systems and Uses Thereof
|
|
US20230414648A1
(en)
|
2020-11-06 |
2023-12-28 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of DM1 with SLUCAS9 and SACAS9
|
|
KR102803305B1
(ko)
*
|
2020-11-25 |
2025-05-07 |
연세대학교 산학협력단 |
트랜스-스플라이싱 아데노-연관 바이러스 벡터를 포함하는 프라임에디팅용 조성물
|
|
US20220238230A1
(en)
*
|
2021-01-15 |
2022-07-28 |
Trustees Of Tufts College |
Methods for modulating the function of biological regulatory networks in health and disease by exploiting their memory properties
|
|
WO2022182957A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
|
US20240165271A1
(en)
|
2021-03-26 |
2024-05-23 |
The Board Of Regents Of The University Of Texas System |
Nucleotide editing to reframe dmd transcripts by base editing and prime editing
|
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
|
WO2022247917A1
(zh)
|
2021-05-28 |
2022-12-01 |
上海瑞宏迪医药有限公司 |
衣壳变异的重组腺相关病毒及其应用
|
|
WO2023280175A1
(en)
*
|
2021-07-06 |
2023-01-12 |
National Institute Of Biological Sciences, Beijing |
Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis
|
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
|
US20240408240A1
(en)
|
2021-10-01 |
2024-12-12 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
|
|
US12285497B2
(en)
|
2021-10-15 |
2025-04-29 |
Research Institute At Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
AU2022371442A1
(en)
|
2021-10-21 |
2024-04-18 |
Vertex Pharmaceuticals Incorporated |
Hypoimmune cells
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
CN118660913A
(zh)
|
2022-02-21 |
2024-09-17 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
GB202202628D0
(en)
*
|
2022-02-25 |
2022-04-13 |
Babraham Inst |
Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety
|
|
EP4490291A1
(en)
|
2022-03-08 |
2025-01-15 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
|
TW202345911A
(zh)
|
2022-03-08 |
2023-12-01 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
|
|
CA3249261A1
(en)
|
2022-04-18 |
2023-10-26 |
Vertex Pharmaceuticals Incorporated |
COMPOSITIONS AND PROCESSES TO IMPROVE ADENE-ASSOCIATED VIRUS (AAV) THERAPY AND REDUCE AAV TROPISM TO THE LIVER
|
|
EP4509606A4
(en)
*
|
2022-04-19 |
2025-12-10 |
Kanglin Biotech Hangzhou Co Ltd |
CONSTRUCTION OF NUCLEIC ACID FOR THE TREATMENT OF AN INHERITED COAGULATION FACTOR DEFICIENCY AND ITS USE
|
|
EP4558634A1
(en)
|
2022-07-18 |
2025-05-28 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
|
KR20250108100A
(ko)
|
2022-09-22 |
2025-07-15 |
디나코 아게 |
Aav 유전자 치료법 벡터를 이용한 심근병증의 치료
|
|
EP4720314A1
(en)
|
2023-05-25 |
2026-04-08 |
Juno Therapeutics, Inc. |
Aav purification method
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
WO2025082618A1
(en)
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025214477A1
(en)
|
2024-04-12 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Treatment of genetic cardiomyopathies with aav gene therapy vectors
|